Likelihood models for detecting positively selected amino acid sites and applications to the HIV-1 envelope gene. NLM AIDSLINE Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Likelihood models for detecting positively selected amino acid sites and applications to the HIV-1 envelope gene.

Genetics. 1998 Mar;148(3):929-36. Unique Identifier : AIDSLINE MED/98198821
Nielsen R; Yang Z; Department of Integrative Biology, University of California, Berkeley; 94720-3140, USA. rasmus@mws4.biol.berkeley.edu

Abstract: Several codon-based models for the evolution of protein-coding DNA sequences are developed that account for varying selection intensity among amino acid sites. The "neutral model" assumes two categories of sites at which amino acid replacements are either neutral or deleterious. The "positive-selection model" assumes an additional category of positively selected sites at which nonsynonymous substitutions occur at a higher rate than synonymous ones. This model is also used to identify target sites for positive selection. The models are applied to a data set of the V3 region of the HIV-1 envelope gene, sequenced at different years after the infection of one patient. The results provide strong support for variable selection intensity among amino acid sites The neutral model is rejected in favor of the positive-selection model, indicating the operation of positive selection in the region. Positively selected sites are found in both the V3 region and the flanking regions.
Keywords: *Evolution, Molecular *HIV Envelope Protein gp120/GENETICS *HIV-1/GENETICS *Models, Genetic *Models, Statistical *Peptide Fragments/GENETICS *Selection (Genetics)KWDevolution,molecularKWDhivenvelopeproteingp120/geneticsKWDhiv-1/geneticsKWDmodels,geneticKWDmodels,statisticalKWDpeptidefragments/geneticsKWDselection(genetics)
980830
M9881122

Copyright © 1998 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .